Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

However, a spokesperson for Novo Nordisk implied the Danish drugmaker plans to continue lobbying for expanded Medicare ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for ...

April 14, 2025 Novo Nordisk warns consumers about counterfeit ... in the government's final reimbursement rates for 2026 Medicare Advantage health plans run by private insurers, more than double ...